1. The CA125 regression rate to predict overall survival differ between paclitaxel-containing regimen and nonpaclitaxel regimen in patients with advanced ovarian cancer. Issue 5 (1st August 2002) Authors: Tsuda, H.; Hashiguchi, Y.; Nakata, S.; Deguchi, M.; Negoro, S.; Ishiko, O.; Yamamoto, K. Journal: International journal of gynecological cancer Issue: Volume 12:Issue 5(2002) Page Start: 435 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗